Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

44%

4 of 9 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 3

4(44.4%)

9Total

Phase 1(5)

Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06247722Active Not Recruiting

Real World Use of Tocilizumab Biosimilar studY

Role: lead

NCT04934072Phase 3Completed

A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis

Role: lead

NCT02660580Phase 3Completed

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Role: lead

NCT04512001Phase 3Completed

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

Role: lead

NCT04018599Phase 1Completed

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Role: lead

NCT03282851Phase 1Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

Role: lead

NCT03052322Phase 3Completed

MSB11022 in Moderate to Severe Rheumatoid Arthritis

Role: lead

NCT03251339Phase 1Completed

Safety and Immunogenicity of MSB11455 in Healthy Participants

Role: lead

NCT03251248Phase 1Completed

Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

Role: lead

NCT03014947Phase 1Completed

MSB11022 in Healthy Subjects

Role: lead

All 10 trials loaded